Similar articles for PMID: 23806328

Year	Number of Results
1812	1
1873	1
1879	1
1893	1
1900	1
1912	1
1917	2
1920	1
1937	1
1959	1
1976	2
1984	1
1985	1
1988	1
1989	1
1991	1
1996	1
1997	2
1999	4
2000	2
2001	3
2002	2
2003	2
2004	3
2005	1
2006	2
2007	9
2008	25
2009	28
2010	12
2011	15
2012	16
2013	24
2014	46
2015	38
2016	35
2017	38
2018	35
2019	26
2020	16
2021	14
2022	19
2023	4
2024	0

1

A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy.

Favato G, Baio G, Capone A, Marcellusi A, Saverio Mennini F. Favato G, et al. Clin Ther. 2013 Jul;35(7):904-14. doi: 10.1016/j.clinthera.2013.05.003. Epub 2013 Jun 24. Clin Ther. 2013. PMID: 23806328

2

Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: the BEST study.

Favato G, Baio G, Capone A, Marcellusi A, Costa S, Garganese G, Picardo M, Drummond M, Jonsson B, Scambia G, Zweifel P, Mennini FS. Favato G, et al. Med Care. 2012 Dec;50(12):1076-85. doi: 10.1097/MLR.0b013e318269e06d. Med Care. 2012. PMID: 22922435

3

Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.

Novaes HM, de Soárez PC, Silva GA, Ayres A, Itria A, Rama CH, Sartori AM, Clark AD, Resch S. Novaes HM, et al. Vaccine. 2015 May 7;33 Suppl 1:A135-42. doi: 10.1016/j.vaccine.2014.12.031. Vaccine. 2015. PMID: 25919154

4

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.

Demarteau N, Van Kriekinge G, Simon P. Demarteau N, et al. Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15. Vaccine. 2013. PMID: 23777952 Free article.

5

Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.

Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB. Aguilar IB, et al. Vaccine. 2015 May 7;33 Suppl 1:A167-73. doi: 10.1016/j.vaccine.2014.12.067. Vaccine. 2015. PMID: 25919157

6

Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.

Haeussler K, Marcellusi A, Mennini FS, Favato G, Picardo M, Garganese G, Bononi M, Costa S, Scambia G, Zweifel P, Capone A, Baio G. Haeussler K, et al. Value Health. 2015 Dec;18(8):956-68. doi: 10.1016/j.jval.2015.08.010. Epub 2015 Oct 21. Value Health. 2015. PMID: 26686779 Free article.

7

Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.

Armstrong EP. Armstrong EP. J Manag Care Pharm. 2010 Apr;16(3):217-30. doi: 10.18553/jmcp.2010.16.3.217. J Manag Care Pharm. 2010. PMID: 20331326 Free PMC article. Review.

8

Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.

Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ. Berkhof J, et al. Vaccine. 2013 Dec 31;31 Suppl 7:H71-9. doi: 10.1016/j.vaccine.2013.04.086. Vaccine. 2013. PMID: 24332299

9

Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).

Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M. Kim JJ, et al. Vaccine. 2013 Dec 30;31 Suppl 6:G65-77. doi: 10.1016/j.vaccine.2012.06.096. Vaccine. 2013. PMID: 24331822

10

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.

Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Goldie SJ, et al. Vaccine. 2008 Jul 29;26(32):4080-93. doi: 10.1016/j.vaccine.2008.04.053. Epub 2008 May 15. Vaccine. 2008. PMID: 18550229

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

399 results

Results by year